ERK-mediated negative feedback regulation of oncogenic EGFRvIII in glioblastoma cells
| Autor: | Satoru Yokoyama, Tomohiro Tanaka, Ratna Dini Haryuni, Yue Zhou, Hiroaki Sakurai |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
MAPK/ERK pathway Cancer Research biology HEK 293 cells Tyrosine phosphorylation Articles Cell cycle 03 medical and health sciences chemistry.chemical_compound 030104 developmental biology 0302 clinical medicine Oncology chemistry Downregulation and upregulation Epidermal growth factor 030220 oncology & carcinogenesis Cancer research biology.protein Phosphorylation Epidermal growth factor receptor |
| Zdroj: | Oncol Lett |
| Popis: | Epidermal growth factor receptor variant III (EGFRvIII) is the most common active EGFR mutant in glioblastoma multiforme (GBM). The expression of this mutant often correlates with a poor patient prognosis due to its ability to extend downstream signaling. The EGFR pathway is controlled by a negative feedback mechanism that restricts the extent and length of downstream signaling. To date, the role of negative feedback in the oncogenic EGFRvIII mutant remains undetermined. The present study indicated that activation of the MEK-ERK pathway led to the phosphorylation of Thr-402, a conserved negative feedback residue in the juxtamembrane domain corresponding to Thr-669 of wild-type EGFR (EGFRwt), which resulted in a rapid reduction in the tyrosine phosphorylation of EGFRvIII in U87MG human glioblastoma and 293 cells. Moreover, despite the incapability of EGFRvIII to bind ligands, EGF was indicated to downregulate the tyrosine phosphorylation of EGFRvIII by activating the EGFRwt-ERK pathway. These results demonstrated a conserved negative feedback mechanism in the activation of EGFRvIII, which presents a new aspect in functional interactions between EGFRvIII and EGFRwt in glioblastoma cells. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|